Xcout Intel
Excellergy
Excellergy is a biotechnology company developing a new therapeutic class known as Effector Cell Response Inhibitors (ECRIs) to treat severe allergic diseases. Its trifunctional mechanism aims to provide rapid and complete control of allergic responses by removing bound IgE from effector cells, neutralizing circulating free IgE, and downregulating receptor expression.
Subscribe to see Excellergy’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Excellergy at a glance
Excellergy is a biotechnology company headquartered in United States. Xcout tracks 8 named people at Excellergy, including TODD ZAVODNICK (Chief Executive Officer).
Excellergy leadership
- TODD ZAVODNICKChief Executive Officer
- Phil BrownChief Medical Officer
- Geoff HarrisChief Scientific Officer & Co-Founder
- Luke PenningtonVice President, Discovery & Co-Founder
- Alex EggelCo-Founder
- Ted JardetzkyCo-Founder
2 more named people on record for Excellergy, with roles, board committees and tenure — see the full roster →
Recent Excellergy news
Excellergy competitors
A few of Excellergy's closest competitors — see the full list of competitors and alternatives →
Allegria Therapeutics is a Swiss biotech company founded in Basel in 2023 that targets mast cells to redefine the treatment of allergic and inflammatory diseases.
Alladapt Immunotherapeutics is a U.S. biotechnology company developing oral immunotherapies for food allergies. Its lead product candidate, ADP101, was designed as a single treatment intended to address multiple food allergies, serving patients with food-allergic disease.
IgGenix is a clinical-stage, venture-backed biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company leverages its proprietary antibody discovery platform with a primary mission to cure allergies and other immunological diseases.
Biothea Pharma, Inc. is a pharmaceutical company developing needle-free, convenient, and cost-effective alternatives for the treatment of severe allergic reactions and anaphylaxis. The company aims to provide improved therapeutic options for patients suffering from life-threatening allergic shocks.
Poplar Therapeutics is a biotechnology company focused on creating the next generation of anti-IgE medicines to treat patients. Headquartered in Cambridge, Massachusetts, the early-stage startup develops novel therapeutics to help patients live free of fear from allergic and immune conditions.
Allakos Inc. is a publicly traded clinical-stage biotechnology company headquartered in Redwood City, California. The company develops therapeutic antibodies that target mast cells and eosinophils to treat severe allergic, inflammatory, and proliferative diseases.
Get Excellergy's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Excellergy in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access